PROVETOP

Biotinylated Human FGFR1 beta (IIIc) Protein

Catalog No: FGFR1-HB002

Species
Human
Expression System
HEK293
Tag
His, Avi
Activity
Activity verified

Product overview

Recombinant Biotinylated Human FGFR1 beta (IIIc) Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Pro156-Thr355 (UniProt accession: P11362-7).

Product Details

Molecular Aliases
FGFR-1; BFGFR; bFGF-R-1; FLT-2; N-sam; CD331;; FGFR1; bFGF-R1; FLT2
Protein Length
Pro156-Thr355
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 25.23 kDa. Due to glycosylation, the protein migrates to 45-55 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22μm filtered solution in PBS, 8% trehalose (pH 7.4).
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
FGFR1-HB002 Bis-Tris-PAGE-white result

Biotinylated Human FGFR1 beta (IIIc) on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA
FGFR1-HB002 ELISA result

Immobilized Biotinylated Human FGFR1 beta (IIIc), His-Avi tag at 1μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-FGFR1 Antibody, hFc Tag with the EC50 of 73.0ng/ml determined by ELISA (QC Test).

Background

Fibroblast growth factor receptor 1 (FGFR1) transmits signals through the plasma membrane regulating essential cellular processes like division, motility, metabolism, and death. Overexpression of FGFR1 is observed in numerous tumors and thus constitutes an attractive molecular target for selective cancer treatment.

References

  1. Pozniak M, Sokolowska-Wedzina A, Jastrzebski K, Szymczyk J, Porebska N, Krzyscik MA, Zakrzewska M, Miaczynska M, Otlewski J, Opalinski L. FGFR1 clustering with engineered tetravalent antibody improves the efficiency and modifies the mechanism of receptor internalization. Mol Oncol. 2020 Sep;14(9):1998-2021. doi: 10.1002/1878-0261.12740. Epub 2020 Jul 3. PMID: 32511887; PMCID: PMC7463352.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support